Association of British Healthcare Industries (ABHI) questions drug authority involvement
This article was originally published in Clinica
Executive Summary
The UK Association of British Healthcare Industries is arguing against the Medicines Control Agency's level of proposed consultation fees for well-established drug-device combinations. It is drawing up a list of combination products where medicinal substances are ancillary to devices for which, in its opinion, consultation and therefore fees should be minimal (or not even necessary).